With “human cryogenic technology”, race with time, let the dead wait for future technology and achieve “resurrection.” Can the scene in science fiction be achieved?

In May this year, the 49-year-old general voluntary worker Zhan Wenlian died in Jinan. After she passed away, she immediately had a cryopreservation of the human body and her body was stored in a liquid nitrogen tank at minus 196 degrees Celsius. This made her become the Chinese who received the first cryopreservation of the human body in China, and was the second Chinese to be cryopreserved after Du Hong, one of the editors of the science fiction “Three-body”. The Shandong Yinfeng Life Science Research Institute, which participated in the operation of cryopreservation of Zhan Wenlian's body, and the Yinfeng Bioengineering Group Co., Ltd. behind it have drawn extensive attention. This company was established in Jinan for only 6 years, how does it create a sensation legend within the industry? What kind of story is behind this?

Cross-discipline from real estate to biomedicine

When it comes to the Yinfeng Group, the first thing that people in Jinan think of is that this is a real estate group that has developed a lot of high-quality real estates. Despite making some psychological preparations, it was until the reporters walked into Yinfeng Bio Group Co., Ltd., located in the Jinan Comprehensive Free Trade Zone, the reporter realized that how far this low-key high-tech enterprise under the Yinfeng Group had gone in biomedical field.

In Shandong Yinfeng Life Science Research Institute, where the body of Zhan Wenlian was preserved, the reporter saw a cryogenic operating room that can be operated at minus 30 degrees Celsius, and the only program cooling instrument in the world that can continuously lower the body temperature from room temperature to minus 190 degrees....”“The advanced device” is dazzling. “At present, there are five human cryopreservation centers in the world, and Shandong Yinfeng Life Sciences Research Institute is the first in Asia.”Li Xia, a researcher at Shandong Yinfeng Life Science Research Institute, said. Yinfeng Biotechnology Group launched a research program on the cryopreservation and resuscitation of human tissues and organs in 2013. At present, it has successfully achieved the cryogenic preservation, resuscitation and clinical application of various human cells. Breakthroughs of research have been achieved in cryogenic preservation and resuscitation of valves, skin, severed fingers (toes), ovarian tissues and some large-sized organs.

Located across a corridor from temporary residence of Zhan Wenlian, is the Shandong Province Cord Blood Hematopoietic Stem Cell Bank (hereinafter referred to as the Shandong Cord Blood Bank), which is managed and operated by the Yinfeng Biotechnology Group. There are hundreds of silver and white liquid nitrogen tanks, which store 300,000 shares of cord blood within province. The development of Yinfeng Bio Group is starting in the field of stem cells and has a profound accumulation in stem cell storage and application fields.

In addition to umbilical cord blood preservation and cryogenic medicine, Yinfeng Biotechnology Group has also achieved some remarkable results in high-tech fields such as gene sequencing technology, cell technology research, and clinical application.

Their first time into the field of stem cells is not favored

Relying on the strong financial strength and capital operation capability of Yinfeng Group, after more than ten years of hard work and struggle, Yinfeng Biotechnology Group now has had Many companies, such as Shandong Qilu Stem Cell Engineering Co., Ltd., Shandong Province Cord Blood Hematopoietic Stem Cell Bank, and Yinfeng Gene Technology Co., Ltd.,  and has developed into the largest and with the strongest technology medical cells resource storage center, gene sequencing center, cell clinical application and research center, and cryogenic medical resource storage and research center within Shandong.

However, over a decade ago, the cross-discipline from real estate and financial sectors to the biomedical fields like stem cells, this kind of action of Yinfeng Group was not favored. “At that time, the stem cell industry was a very frontier field. Many medical personnel were utterly ignorant of what a cord blood and hematopoietic stem cell is and what a cord blood bank is, and our business was difficult to carry out.”Sheng Dewei, vice president of Yinfeng Group and chairman of Yinfeng Biotechnology Group, recalled.

In the face of numerous difficulties, the management team of Yinfeng Biotechnology Group did not give up. “We all know that this is a life-saving blood, so we cannot afford to give up even with more difficulties.”They became the commentators of umbilical cord blood stem cells. A hospital by a hospital to interpret and tried to convey professional knowledge of stem cell to every medical staff and let them know its medical value. With such persistence and hard work, Yinfeng Biotechnology Group successfully passed the initial stage of the loss and gained recognition from the industry.

R&D focused on the transformation and application 

With the success of China's first self-contained human cryopreservation surgery, the previously unknown Yinfeng Biotechnology Group has been a startling success. The reporter learned in the interview that Yinfeng Biotechnology Group's innovative ideas are indeed different. “For the leading companies in each segment, continuous innovation is necessary. We also value innovation. The difference is that our innovation is more biased toward the transformation of scientific research results, which allows more people can enjoy the benefits of scientific development.”The management team of Yinfeng Biotechnology Group said that.

“In the field of biopharmaceuticals, we have to invest heavily with a long research and development cycle in high risks. Therefore, we will focus our R&D system on the transformation and application of results.”Pang Yong, President of Yinfeng Biotechnology Group explained. This means that Yinfeng Bio will serve as a bridge between basic research and clinical applications. They must keep an eye on the scientific research achievements of universities and research institutes, and the other eye must focus on the needs of the market.

However, this does not mean to be the “speculative dealers” of technology. After obtaining the technical achievements, Yinfeng Biotechnology Group will further develop and apply the technology to the clinic. “Just like Huawei mobile phones, many components are not developed by Huawei, the screen may be Samsung or LG, the camera may be Sony, but they have their own unique technology that can integrate all kinds of technology to make high-end mobile phone products.” Sheng Dewei said.

A transformation application, which sounds simpler than basic research and development, is actually not easy. “At the beginning, many people were pessimistic about the road we chose because it was too difficult to determine how future of a technology is in the early stages. It's like Jack Ma and Ma Huateng, when they just start their own businesses, can anyone imagine that they can do it as today?”Sheng Dewei said that now it seems that for the success of Yinfeng Biotechnology Company, the vision, opportunities, and persistence are indispensable.

What behind the persistence is the sticking to integrity and quality

 “If the enterprise wants to last longer, the core values are important. The greatest impression Yinfeng Biotechnology Group gives me is the pursuit of perfectionism.”Pang Yong, who had worked in other pharmaceutical companies, said.

For Sheng Dewei, this kind of perfectionism is not only reflected in the pursuit of technology.”Relying on technology, many companies can be excellent, but if you want to run a company for a long time, what you need is out of the technology.”

Integrity and quality are what YinFeng Biotechnology Group has been pursuing. In 1998, Yinfeng Biotechnology Group established an HLA laboratory. However, there's no relevant technical specification and standards in the country. Therefore, companies have to hire foreign experts to help us with the construction.“At first, a US expert was invited to spend three months, investing more than 1 million for laboratories Decoration and found that it did not meet the requirements. Well, they have to reluctantly torn down the newly built laboratory and started again. Another German expert was invited and it finally took half a year to complete.”Sheng Dewei said that behind that persistent is the adherence to integrity and quality, which is also the enterprise spirit that Yinfeng Biotechnology Group has always followed.

 “Our products are medical products that are directly applied to the patient's body and related to the survival of the patient. Therefore, they cannot be sloppy and must strictly control the quality.”More than 95% of our equipment is imported equipment. The quality is world-class. Whenever our team works, we treat every sample carefully and pay attention to quality and strive to be the best.”Sheng Dewei said that Yinfeng Biotechnology Group hopes to become the industry leader in the field of clinical application of cells and the use genes in diagnosis and prevention of diseases. However, for enterprises, the most important thing is to in line with the core concept of corporate culture - “guarantee for the integrity and quality”, only this can afford their own conscience.

 [Reporter's notes]

Success is from the pursuit of perfection

Even the staff of Yinfeng Biotechnology admits that this company does meet the definition of the invisible champion: it keeps low-profile and not known to consumers, but it has achieved the “top three” of market segments with dedication and high-end quality.

Many companies can also achieve such a standard. However, in reality, technologically advanced companies may not be able to win in fierce market competition. In the interview, the reporter always wanted to find out in the highly competitive field of biomedicine. What the secret of the rise of this “cross-disciplinary” enterprise has.